Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Pfizer's Tukysa improved progression-free survival in first-line HER2+ metastatic breast cancer, showing strong efficacy an...
Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at least...
Pfizer Inc. (NYSE:PFE) today announced positive topline results from the Phase 3 HER2CLIMB-05 trial of first-line combination t...
Presentation to include new patient-reported outcomes (PRO) data from the Phase 3 VERITAC-2 clinical trial
Pfizer Inc. (NYSE:PFE, "Pfizer"))) will present data across its infectious disease portfolio at the upcoming IDWeek 202...
https://www.youtube.com/watch?v=XOtOCzut9pM
Trump to announce new deal with AstraZeneca to lower prescription drug costs for Americans using most-favored-nation pricing mo...
Morgan Stanley analyst Terence Flynn maintains Pfizer (NYSE:PFE) with a Equal-Weight and lowers the price target from $33 to...
Pharmacies and GoodRx are in talks to join TrumpRx, a new drug pricing site aiming to lower prescription costs for U.S. consumers.
